Juvaris BioTherapeutics, Inc. announced that The Centers for Disease Control and Prevention and Juvaris BioTherapeutics, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) for the evaluation of a JVRS-100 adjuvanted H5N1 pandemic influenza vaccine. The ability of JVRS-100 to aid in the induction of a protective antibody response to the H5N1 vaccine at low doses of vaccine will be confirmed.